KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $13.3 million.

  • Twist Bioscience's Share-based Compensation rose 1069.14% to $13.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $65.7 million, marking a year-over-year increase of 2667.84%. This contributed to the annual value of $64.5 million for FY2025, which is 2657.63% up from last year.
  • Per Twist Bioscience's latest filing, its Share-based Compensation stood at $13.3 million for Q4 2025, which was up 1069.14% from $16.1 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Share-based Compensation registered a high of $22.5 million during Q1 2022, and its lowest value of -$2.3 million during Q4 2022.
  • Its 5-year average for Share-based Compensation is $13.4 million, with a median of $12.8 million in 2024.
  • Per our database at Business Quant, Twist Bioscience's Share-based Compensation tumbled by 11283.96% in 2022 and then surged by 57397.85% in 2023.
  • Over the past 5 years, Twist Bioscience's Share-based Compensation (Quarter) stood at $18.1 million in 2021, then crashed by 112.84% to -$2.3 million in 2022, then soared by 573.98% to $11.0 million in 2023, then grew by 8.81% to $12.0 million in 2024, then increased by 10.69% to $13.3 million in 2025.
  • Its last three reported values are $13.3 million in Q4 2025, $16.1 million for Q3 2025, and $16.1 million during Q2 2025.